Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 2586116 in Moderate to Severe Obstructive Sleep Apnea
NCT04713826Phase 2Completed
- Sponsor
- Bayer
- Start
- Mar 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of BAY2586116 in obstructive sleep apnea (OSA), sponsored by Bayer. Started Mar 2021; status: completed.
02
Drugs
BAY2586116
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT04713826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04713826.